Delving into the Latest Updates on Jiangzhong Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Respiratory Diseases

Infectious Diseases

Mouth and Tooth Diseases

Herbal medicine

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	3
Nervous System Diseases	1

Top 5 Drug Type	Count

Herbal medicine	3
Small molecule drug	1

Top 5 Target	Count

Sodium channels	1

本试验旨在研究单次空腹口服晋城海斯制药有限公司研制、生产的雷贝拉唑钠肠溶片（20 mg）的药代动力学特征；以卫材（中国）药业有限公司生产的雷贝拉唑钠肠溶片（波利特®，20 mg）为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性。

[Translation]

The purpose of this study was to study the pharmacokinetic characteristics of a single fasting oral administration of rabeprazole sodium enteric-coated tablets (20 mg) developed and produced by Jincheng Haisi Pharmaceutical Co., Ltd.; using rabeprazole sodium enteric-coated tablets (Polite®, 20 mg) produced by Eisai (China) Pharmaceutical Co., Ltd. as the reference preparation, to compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations, and to evaluate the bioequivalence of the two preparations in humans.

Start Date03 Aug 2022

Sponsor / Collaborator

Jincheng Haisi Pharmaceutical Co. Ltd.

100 Clinical Results associated with Jiangzhong Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Jiangzhong Pharmaceutical Co., Ltd.

Login to view more data

65

Literatures (Medical) associated with Jiangzhong Pharmaceutical Co., Ltd.

01 Jun 2024·Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan

Identifying the geographical origin and processing technology of Moyao () on the basis of near-infrared spectroscopy combined with chemometrics.

Article

Author: Shaomin, Cheng ; Ganming, Yan ; Changzheng, L U ; Fengjie, X U ; Xinjiang, Qiao ; Ningning, X U ; Linfeng, Deng

OBJECTIVETo evaluate the quality of Moyao (Myrrh) in the identification of the geographical origin and processing of the products.METHODSRaw Moyao (Myrrh) and two kinds of Moyao (Myrrh) processed with vinegar from three countries were identified using near-infrared (NIR) spectroscopy combined with chemometric techniques. Principal component analysis (PCA) was used to reduce the dimensionality of the data and visualize the clustering of samples from different categories. A classical chemometric algorithm (PLS-DA) and two machine learning algorithms [K-nearest neighbor (KNN) and support vector machine] were used to conduct a classification analysis of the near-infrared spectra of the Moyao (Myrrh) samples, and their discriminative performance was evaluated.RESULTSBased on the accuracy, precision, recall rate, and F1 value in each model, the results showed that the classical chemometric algorithm and the machine learning algorithm obtained positive results. In all of the chemometric analyses, the NIR spectrum of Moyao (Myrrh) preprocessed by standard normal variation or Multivariate scattering correction combined with KNN achieved the highest accuracy in identifying the geographical origins, and the accuracy of identifying the processing technology established by the KNN method after first-order derivative pretreatment was the best. The best accuracy of geographical origin discrimination and processing technology discrimination were 0.9853 and 0.9706 respectively.CONCLUSIONSNIR spectroscopy combined with chemometric technology can be an important tool for tracking the origin and processing technology of Moyao (Myrrh) and can also provide a reference for evaluations of its quality and the clinical use.

15 May 2024·ACS Chemical Neuroscience

Synthesis and Neuroprotective Evaluation of Substituted Indanone/Benzofuranone and Piperidine Hybrids

Article

Author: Zeng, Qing ; Cai, Zhifang ; Xiong, Jian ; Yang, Zunhua ; Feng, Yulin ; Li, Huilan ; Zhang, Ziwei ; Fang, Yuanying ; Hu, Pei ; Wan, Yang

Based on the neuroprotection of butylphthalide and donepezil, a series of indanone/benzofuranone and piperidine hybrids were designed and synthesized for assessment of their neuroprotective activities, aiming to enhance the bioavailability and therapeutic efficacy of natural phthalide analogues. Within this study, it was observed that most indanone derivatives bearing 1-methylpiperidine in the tail segment demonstrated superior neuroprotective effects on the oxygen glucose deprivation/reperfusion (OGD/R)-induced rat primary neuronal cell injury model in vitro compared to benzofuranone compounds. Among the synthesized compounds, 11 (4, 14, 15, 22, 26, 35, 36, 37, 48, 49, and 52) displayed robust cell viabilities in the OGD/R model, along with favorable blood-brain barrier permeability as confirmed by the parallel artificial membrane permeability assay. Notably, compound 4 showed significant neuronal cell viabilities within the concentration range of 3.125 to 100 μM, without inducing cytotoxicity. Further results from in vivo middle cerebral artery occlusion/R experiments revealed that 4 effectively ameliorated ischemia-reperfusion injury, reducing the infarct volume to 18.45% at a dose of 40 mg/kg. This outcome suggested a superior neuroprotective effect compared to edaravone at 20 mg/kg, further highlighting the potential therapeutic efficacy of compound 4 in addressing neurological disorders.

09 May 2024·Journal of Medicinal Chemistry

Discovery of Selective Proteolysis-Targeting Chimera Degraders Targeting PTP1B as Long-Term Hypoglycemic Agents

Article

Author: Zeng, Qing ; Wu, Jiamin ; Cheng, Shaobing ; Feng, Yulin ; Li, Huilan ; Fang, Yuanying ; Yang, Zunhua ; Cai, Zhifang ; Zhang, Ziwei ; Xiong, Jian ; Hu, Pei ; Ying, Yuqi

PTP1B, a promising target for insulin sensitizers in type 2 diabetes treatment, can be effectively degraded using proteolysis-targeting chimera (PROTAC). This approach offers potential for long-acting antidiabetic agents. We report potent bifunctional PROTACs targeting PTP1B through the E3 ubiquitin ligase cereblon. Western blot analysis showed significant PTP1B degradation by PROTACs at concentrations from 5 nM to 5 μM after 48 h. Evaluation of five highly potent PROTACs revealed compound 75 with a longer PEG linker (23 atoms), displaying remarkable degradation activity after 48 and 72 h, with DC₅₀ values of 250 nM and 50 nM, respectively. Compound 75 induced selective degradation of PTP1B, requiring engagement with both the target protein and CRBN E3 ligase, in a ubiquitination and proteasome-dependent manner. It significantly reduced blood glucose AUC_0-2h to 29% in an oral glucose tolerance test and activated the IRS-1/PI3K/Akt signaling pathway in HepG2 cells, showing promise for long-term antidiabetic therapy.

100 Deals associated with Jiangzhong Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Jiangzhong Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

3

Approved

Other

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Compound Caoshanhu Guccal Tablets	Pharyngitis More	Approved
Chloroprocaine Hydrochloride ( Sodium channels )	Anesthesia More	Approved
FuFangCaoShanHu	Pharyngitis More	Approved
Bailixiang Herbal Tea	Common Cold More	Phase 2
Recombinant reteplase(Jiangsu Jiangzhong Group Co., Ltd.) ( PLG )	Myocardial Infarction More	Pending